Oleuropein impact on colorectal cancer

Abstract

Colorectal cancer (CRC) is considered the third most common cancer in the world. In Mediterranean region, olives and olive oil play a substantial role in diet and medical traditional behaviors. They totally believe that high consumption of olive products can treat a wide range of diseases and decrease risk of illness. Oleuropein is the main active antioxidant molecule found in pre-mature olive fruit and leaves. Recently, it has been demonstrated that oleuropein is used in cancer therapy as an anti-proliferative and apoptotic agent for some cancer cells. In this review, we would like to explore the conclusive effects of oleuropein on CRC with respect to in vitro and in vivo studies.

Executive summary

Colorectal cancer

• Colorectal cancer (CRC) is considered the third most common cancer in the world.

• Colorectal cancer treatment options involve targeted therapy, immune- and gene therapy.

• Consumption of olive products can treat a wide range of diseases and decrease risk of illness.

Oleuropein against colorectal cancer

• Oleuropein is the primary effective antioxidant molecule in pre-mature olive fruits and leaves.

• Oleuropein was proven to be used in cancer treatment as anti-proliferative and an apoptotic enhancer in several cancer cells.

• Several biological receptors were verified to be involved in OLR action against CRC.

In vitro & in vivo experiments against colorectal cancer

• OLR suppress the proliferation of CRC cells by preventing DNA generation and protein expression.

• OLR blocked the growth and diversity of 84% of colonic tumors.

• OLR has a good synergistic effect when merged with anticancer agents.

• High concentrations of OLR administered in vivo were demonstrated to be safe, and studies on rodents showed that it had an excellent safety profile.

Keywords: :

• apoptosis
• colorectal
• Olea europaea
• oleuropein
• olive oil

Author contributions

H Nsairat, AM Jaber, H Faddah and S Ahmad all contributed in similarly to this work through surveying, searching, data collection, writing and finalizing the first draft.

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this man.